The estimated Net Worth of Charles R Greiner is at least $413 Tisíc dollars as of 6 May 2016. Charles Greiner owns over 3,508 units of Angiodynamic Inc stock worth over $155,152 and over the last 11 years Charles sold ANGO stock worth over $257,884.
Charles has made over 6 trades of the Angiodynamic Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Charles sold 3,508 units of ANGO stock worth $43,183 on 6 May 2016.
The largest trade Charles's ever made was exercising 14,100 units of Angiodynamic Inc stock on 3 August 2015 worth over $215,307. On average, Charles trades about 2,178 units every 73 days since 2013. As of 6 May 2016 Charles still owns at least 20,910 units of Angiodynamic Inc stock.
You can see the complete history of Charles Greiner stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman a Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: